Ampligen Combo Safe, Effective in Treating Recurrent Ovarian Cancer, Phase 1 Study Shows

Ampligen Combo Safe, Effective in Treating Recurrent Ovarian Cancer, Phase 1 Study Shows
A combination of Hemispherx Biopharma's investigational treatment Ampligen (rintatolimod) with chemo-immunotherapy is safe and effective in treating women with recurrent ovarian cancer, according to the final report of a Phase 1 study. While chemotherapy and immunotherapies have shown promise in fighting ovarian cancers, their activity may be boosted by increasing the number of immune cells infiltrating the tumors, researchers say. Ampligen — approved in Argentina for severe cases of chronic fatigue syndrome — is an immune modulator that activates specific immune cells. It is expected to facilitate immune cell infiltration within the tumor. Preclinical studies showed that Ampligen selectively reprogrammed the tumor’s microenvironment by promoting the accumulation of killer T-cells — immune cells that attack cancer cells — without attracting regulatory T-cells (Tregs). Tregs are potent immunosuppressive cells that contain immune responses, namely those against tumors. These findings suggest that adding Ampligen to chemo-immunotherapy could give the immune system an additional advantage in the fight against ovarian cancer. The Phase 1/2 study (NCT02432378), conducted at the University of Pittsburgh Medical Center, evaluated the safety and effectiveness of adding Amp
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *